Hi
@Titans19 .
Respect again and Thankyou for all of your work in posting your thoughts and research .
Just - ** You’re thinking is limited , when considering ‘funds” .
The company have stated and , see EW’s post here also- this is the Race Directors and management’s huge work as well as their investment here , to bring the drug (Bisantrene) through all steps from trial instigation to potential approvals for multiple cancers.
Dr John Cullity , is key as you remind us , and he is also specialised in oncology and works exclusively in major partnering and huge pharmaceutical deals on new drugs.
He is exactly who is needed in the mix .
(Race oncology could never afford his wages if had to pay him - he not only chooses to work for Race oncology, has sunk in his own money ! , personally funded the company again in August last year , as well as with all the management team is only working for out of the money options (NO salaries ) .
Prof Borje Andersson - is a pre-eminent world oncologist and the inventor even of drug treatment now global standard as the co- treatment when patients receive stem / bone cell transplants which now means survival rates are now 99% post stem cell transplant;
vs 30-40+ % + mortalities into the late 90s /00s when his drug was approved ! Borje is now RAC’s head of Clinical treatment- for design , overview all trials , probably chair a world committee ultimately for Bisantrene for Race etc .
He is
Excited - and utterly keen to bring Bisantrene into his clinic at MD Anderson Cancer Centre , and to work to bring Bisantrene back and to market .
He has worked directly with bisantrene when the drug was given to cancer patients into the early 1990s , AML most pertinently , with him in the past !
** Race and he have a world of data - from over 40 clinical trials already conducted in the past including into phase 3 - the current Israel trial is only the first in modern times now .
I don’t believe there will be a hasty, raise money quick below the market level sp . And not right now .
It would be insulting to the huge holdings and hardwork being done by our Board.
No one including these men - wants to see wham bam get in money quickly at all costs , and Dr Peter Molloy (CEO ) as well as Dr Daniel T here repeatedly are firm that money is not needed nearterm .
Any funds be only when purpose required and they are not going to sell any shares or a share of this company away cheaply . No way .
They also feel very responsible to all shareholders in this regard- to protect their investment and respect the huge potential values here .
The numbers of shares you mention additionally - no way!
CR level - thinking that be knockdown shares available , though you’ve come up 10c
- but still thinking with limitation .
Shares do not have to ,nor should , be given away to investors who are not of high conviction in regards to all that Race Oncology is doing .
***This is probably the best company I’ve ever owned , in terms that I can Trust - that the Management truly really to not be going to let Shares go for cheap to new investors . They put their own money in first when pathway was changed and improved after FDA meetings for the IND .
They will protect all shareholders and their significant personal investments including their hardwork for some years .
*This is about :
Building nearterm - a multi hundred million dollar cancer drug company , heading into the billions of dollars in future value for any acquirer .
This is why Race exists .
It’s a big job and worthwhile and important- it is not limited to only raising small amounts of money to keep plugging away . What is required - is Big . The work to do requires more skill and connections and cooperation to set up and run trials . Race can manage small trials .
If a large trial - who will help fund will be very interesting .
The wheels are starting to turn and obviously we look forward to how these men get Bisantrene into the clinics in multiple countries .
With Israel trial news - although this refractory / relapsed AML Bisantrene trial not being run by Race , RAC are only supplying the drug —
RAC own Bisantrene - and will be sharing in ultimate data :
You would think Borje Andersson must know how it is progressing !!
Dr Molloy has said in the shareholder presentation he will be surprised if the trials they need to fund cost even $10 million . In total . Best wishes to you and all .
(20min delay)